Oracle Corporation (NYSE:ORCL) Launches Clinical One Data Collection Cloud Platform


Oracle Corporation (NYSE:ORCL) has unveiled the Clinical One Data Collection Cloud Solution that will help in addressing the challenges presented by electronic data capture for clinical trials.

Clinical One platform to revolutionize data collection

Nowadays, the EDC systems incorporate several virtual components in capturing data due to the fast pace with which patient data is flowing amid a growing number of sources like wearables. As a result, Oracle Health Sciences’ Clinical One service will redefine how technology aids in clinical research. This will enhance efficacy as well as accelerate the delivery of novel therapies.

Michele Taylor-Scott, the Health Decisions’ data management head, indicated that the Oracle Clinical One solution will be a game-changer. She indicated that they have already employed the platform in single randomization as well as trial supply management, and results have been encouraging in terms of data collection. Michele added that the platform is user friendly, and they are optimistic that it will help in minimizing timelines for building databases as well as timelines for database lock, which are vital in clinical studies.

The data management head confirmed that with Clinical One, they will be able to build a complete study in weeks rather than months. Equally, it will be easy to make post-production or mid-study changes in real-time without the long process of migration.

Oracle pioneering in eClinical tech

Oracle is a pioneer in eClinical technology, which is still in the early stages. eClinical tech has not maintained pace with the growth of clinical research and science, which results in high trial costs. Gartner’s Industry Vision report for 2020 indicates that the rate of current trial cost has been increasing unsustainable. As a result, clinical leaders have to challenge the current models for new approaches to take hold.

Taylor-Scott indicated that the use of the Clinical One platform will have a huge impact on the randomization and data collection processes. This applies to the current as well as future clinical studies in the effort to deliver new health therapies for women in the market.